Josh combines two decades of corporate, commercial and technology law practice with the experience having run a public company to bring his clients focused, practical counsel to help them grow their business and maximize their value and returns. His practice focuses on representing clients in life sciences, agribusiness and food and information technology sectors. Josh’s work spans a broad array of technology, intellectual property and commercial transactions ranging from agricultural technology to medical devices, biotechnology and pharmaceuticals, software, Internet and new media transactions and includes developing and implementing business strategies for commercialization of multiple intellectual property platforms. Notably, he represented Nektar Therapeutics in its multi-billion dollar global strategic development and collaboration with Bristol-Myers Squibb for the commercialization of a combination therapy using BMS and Nektars’ proprietary drugs, and Monsanto Company in its efforts to advance agriculture research and development leveraging gene-editing technology through a joint venture with Pairwise Plants. Josh also has negotiated research, funding and commercialization agreements, licenses and technology spin-outs, as well as developed strategies to exploit proprietary products growing out of the research programs of agri-tech and bio-tech clientele. He also advises clients on general corporate matters.
Josh leads the firm’s Global Agribusiness and Food industry group, which has been acknowledged as the only law firm consistently ranked Band 1 in the category by Chambers Global (2016–2019). He has been recognized for his work by several publications, including recommendations by IAM Patent 1000 (2020) and LMG Life Sciences as a “Life Science Star — Finance and Transactional” (2013–2019). Managing Intellectual Property – IP Handbook named Josh a “California: IP Star” (2013–2020), most recently as a “Transactions Star” (2020).
